Evidence map›Paper›PMID 29637449›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2018

Healthcare resources utilisation in primary progressive multiple sclerosis.

Carlo Piccinni, Giulia Ronconi, Silvia Calabria, Letizia Dondi, Emanuele Forcesi, Elisa Rossi, Antonella Pedrini, Nello Martini

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Observational
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Global & regional health technology assessment
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Carlo PiccinniCORE srl-Collaborative Outcome Research, Via Magnanelli 2, 40033 Casalecchio di Reno, Bologna, Italy. piccinni@coreteam.it.ORCID http://orcid.org/0000-0002-8648-8961
Giulia RonconiCORE srl-Collaborative Outcome Research, Via Magnanelli 2, 40033 Casalecchio di Reno, Bologna, Italy.
Silvia CalabriaCORE srl-Collaborative Outcome Research, Via Magnanelli 2, 40033 Casalecchio di Reno, Bologna, Italy.
Letizia DondiCORE srl-Collaborative Outcome Research, Via Magnanelli 2, 40033 Casalecchio di Reno, Bologna, Italy.
Emanuele ForcesiCORE srl-Collaborative Outcome Research, Via Magnanelli 2, 40033 Casalecchio di Reno, Bologna, Italy.
Elisa RossiHealth Care Department, CINECA-Interuniversity Consortium, Casalecchio di Reno, Bologna, Italy.
Antonella PedriniCORE srl-Collaborative Outcome Research, Via Magnanelli 2, 40033 Casalecchio di Reno, Bologna, Italy.
Nello MartiniCORE srl-Collaborative Outcome Research, Via Magnanelli 2, 40033 Casalecchio di Reno, Bologna, Italy.
Cineca · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epidemiological data on primary progressive multiple sclerosis (PPMS) are scarce. This study was aimed to evaluate the burden of PPMS in Italy with healthcare resources utilisation and costs for Italian National Health System (INHS). A 2-year cross-sectional analysis of real-world data collected in the ARCO database, covering > 10 million Italian inhabitants, was performed. From a cohort of patients affected by MS in 2014, those supposedly affected by PPMS were defined by the concurrent matching of absence of disease-modifying treatments and use of rehabilitation services. Any other drug prescriptions, outpatient services and hospitalisations were analysed in 2015 for each subject. The average annual cost per patient was provided both for each expenditure item and by integrating these. Of 13,253,591 inhabitants, 18,453 resulted affected by MS (prevalence 139 × 100,000). Of these, 1849 agreed with additional criteria to identify PPMS (10% of MS population). The 26.8% of these experienced at least one admission in 1 year, 97.3% used at least one outpatient service and 94.3% received at least one reimbursed drug. In the perspective of INHS, PPMS generated an average annual cost of € 3783 per person: 49% for hospitalisations, 28% for outpatient services and 23% for drugs. This study provides a reliable estimation of the PPMS burden in Italy, in terms of healthcare utilisation and direct costs. These findings could be useful to estimate the changes in health expenditure following the incoming of new drugs to treat PPMS with increase of pharmaceutical cost and potential decrease of rehabilitation and hospitalisation costs.

Indexed as

Patient Acceptance of Health CareAdultCohort StudiesCost of IllnessCross-Sectional StudiesFemaleHealth Care CostsHumansItalyMaleMultiple Sclerosis, Chronic ProgressivePrevalenceAdministrative databasesBurden of diseaseItalyPrimary progressive multiple sclerosisReal-world evidence

Identifiers

PMID29637449
OpenAlexW2797560674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.